Are younger or older Australians more likely to receive treatment for amphetamine use?
In 2017-18, Australians aged 20-29 years and 30-39 years were most likely to receive treatment for amphetamine† use than other age groups, accounting for 35% and 38% of amphetamine-related treatment episodes, respectively.
In 2017-18, 5% of Australians who received treatment for amphetamine use were aged 10-19 years, 35% were aged 20-29 years, 38% were aged 30-39 years, 18% were aged 40-49 years, and 4% were aged 50+ years.
Source: Australian Institute of Health and Welfare (AIHW). Alcohol and Other Drug Treatment Services in Australia 2017-18.
† Amphetamines are Central Nervous System (CNS) stimulants that increase neurotransmitter activity. Methamphetamine is a more potent form of amphetamine. The National Minimum Data Set does not provide data on methamphetamine use alone. Instead, treatment episodes due to methamphetamine use are subsumed within ‘amphetamines’. This category includes amphetamine, dexamphetamine, methamphetamine, amphetamine analogues, and amphetamines not elsewhere classified.
Please note: The percentages reported differ to that reported in the Alcohol and Other Drug Treatment Services in Australia 2017-18 report. The AIHW percentages were based on a reduced sample of client records with a valid statistical linkage key whilst the percentages reported above include the complete sample who reported their age.
Treatment Episode: A period of contact between a client and a treatment provider. Only ‘closed’ treatment episodes are included in the data used here. An episode is closed if there is a change in the principal drug of concern, main treatment, or service delivery setting; if the treatment ends; or if the patient is imprisoned or dies.